Analysts Offer Predictions for TNDM FY2025 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Stock analysts at Leerink Partnrs issued their FY2025 earnings per share (EPS) estimates for shares of Tandem Diabetes Care in a research report issued on Monday, July 14th. Leerink Partnrs analyst M. Kratky expects that the medical device company will earn ($1.30) per share for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2027 earnings at ($0.01) EPS.

A number of other analysts have also recently weighed in on TNDM. Piper Sandler decreased their price target on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an “overweight” rating for the company in a research report on Thursday, May 1st. Wall Street Zen cut shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research report on Saturday, June 21st. Truist Financial initiated coverage on shares of Tandem Diabetes Care in a research report on Monday, June 16th. They set a “hold” rating and a $24.00 price target for the company. Robert W. Baird decreased their price target on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a “neutral” rating for the company in a research report on Thursday, May 1st. Finally, Mizuho initiated coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a “neutral” rating and a $20.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of “Hold” and a consensus price target of $32.71.

Tandem Diabetes Care Stock Up 3.6%

Shares of Tandem Diabetes Care stock opened at $15.75 on Wednesday. The company has a fifty day moving average price of $19.93 and a 200 day moving average price of $24.04. The company has a current ratio of 2.30, a quick ratio of 1.81 and a debt-to-equity ratio of 1.99. Tandem Diabetes Care has a twelve month low of $14.87 and a twelve month high of $48.24. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -5.67 and a beta of 1.48.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). The firm had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative return on equity of 57.33% and a negative net margin of 18.71%. The company’s quarterly revenue was up 22.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.65) earnings per share.

Hedge Funds Weigh In On Tandem Diabetes Care

Several large investors have recently modified their holdings of the stock. State of Alaska Department of Revenue lifted its position in shares of Tandem Diabetes Care by 9.0% during the second quarter. State of Alaska Department of Revenue now owns 39,660 shares of the medical device company’s stock worth $739,000 after purchasing an additional 3,269 shares during the last quarter. Banque Pictet & Cie SA bought a new position in shares of Tandem Diabetes Care during the second quarter worth about $1,566,000. Diversified Trust Co lifted its position in shares of Tandem Diabetes Care by 11.8% during the second quarter. Diversified Trust Co now owns 16,348 shares of the medical device company’s stock worth $305,000 after purchasing an additional 1,725 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Tandem Diabetes Care during the second quarter worth about $585,000. Finally, Voya Investment Management LLC lifted its position in shares of Tandem Diabetes Care by 39.2% during the first quarter. Voya Investment Management LLC now owns 136,698 shares of the medical device company’s stock worth $2,619,000 after purchasing an additional 38,519 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.